EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Muscle health in the modern era of incretin‐based therapies

Giuseppe De Girolamo iD, Moris Sangineto iD, Giuseppe Di Gioia, Rossella Bianco, Martina Ciarnelli, Gaetano Serviddio

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70155 ↗

At a glance

Übersichtsarbeit in European Journal of Clinical Investigation, published online on 2025-12-02. Written by Giuseppe De Girolamo and 5 co-authors. Institution: Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Major MEDLINE topics: Incretins, Muscle, Skeletal, Obesity, Weight Loss. Cited 13 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Intentional weight loss improves obesity‐related outcomes but reduces lean body mass, raising concern about skeletal muscle mass, function and long‐term health. GLP‐1 receptor agonists (GLP‐1RAs) produce clinically meaningful weight loss primarily by lowering energy intake and slowing gastric emptying, with additional benefits on insulin sensitivity and inflammation.

Objective

To clarify GLP‐1RAs' effects on skeletal muscle tissue, body composition and physical function by reviewing preclinical and clinical evidence.

Findings

Across randomized and controlled studies, GLP‐1RAs reduce fat mass more than lean body mass. Functional measures appear preserved. Preclinical and early clinical data suggest improvements in muscle quality (microvascular recruitment, mitochondrial efficiency, reduced intramuscular fat) rather than hypertrophy.

Conclusions

GLP‐1RA‐induced weight loss is largely fat mass with modest absolute lean body mass decline and no consistent deterioration in strength or function. Progressive resistance training, adequate/high‐quality protein and periodic monitoring of body composition and performance should accompany therapy, especially in higher‐risk patients.

Subjects

MeSH terms (MEDLINE)

IncretinsMuscle, SkeletalObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHumansBody CompositionMuscle StrengthInsulin Resistance

Author keywords

GIPGLP‐1GLP‐1RAmuscle lossweight loss

Substances

IncretinsGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID profiles: Giuseppe De Girolamo, Moris Sangineto

Cite

APA

De Girolamo, G., Sangineto, M., Di Gioia, G., Bianco, R., Ciarnelli, M., & Serviddio, G. (2026). Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70155

Vancouver

De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70155

BibTeX
@article{DeGirolamo2026,
  author = {De Girolamo, Giuseppe and Sangineto, Moris and Di Gioia, Giuseppe and Bianco, Rossella and Ciarnelli, Martina and Serviddio, Gaetano},
  title = {Muscle health in the modern era of incretin‐based therapies},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70155}
}
Start for free →